Myasthenia gravis is a heterogeneous disorder associated with several distinct antibodies and immunopathogenic mechanisms that are dependent on T cells and mediated by B cells. Besides conventional therapies, the emergence of molecular therapeutics has prompted the development of innovative medications that target key elements of myasthenia gravis pathogenesis. In The Lancet Neurology, Ali A Habib and colleagues1 report findings from the LUMINESCE trial that investigated the use of satralizumab, a monoclonal antibody that blocks the IL-6 receptor in patients with seropositive generalised myasthenia gravis.